Navelbine (chemical name: vinorelbine) chemotherapy combined with Herceptin has been studied recently in clinical trials. There are only phase II studies of this combination.
In one study, women with metastatic HER2 positive breast cancer received both Herceptin and Navelbine weekly. The drug combination shrank the tumors in 75% of the women. The most common side effect, which occurred in about one quarter of the women, was neutropenia. Another study reported an overall response rate of 78 percent in women with HER2 positive metastatic breast cancer and was presented at the 24th Annual San Antonio Breast Cancer Symposium. The combination is currently being tested in a phase III study: Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer, NCT00148668. The purpose of this study is to find out what effects the preoperative combination therapies of herceptin/navelbine or herceptin/taxotere/carboplatin will have on patients with early stage HER-2 positive breast cancer.
Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 19:2722-2730, 2001.